2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…2019 American Transplant Congress
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
*Purpose: Rabbit anti-thymocyte globulin (rATG) cumulative dose needed to effectively and safely prevent acute cellular rejection is unknown. This study compares the efficacy of total…2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
1Tampa General Hospital, Tampa, FL, 2Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…2019 American Transplant Congress
No Indication of Increased CMV Infection in Kidney Transplant Recipients without Pharmacological Prophylaxis Receiving a Single 3mg/kg Dose of Rabbit Anti-Thymocyte Globulin (ATG) Instead of No-Induction
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Induction therapy with rabbit anti-thymocyte globulin (ATG) in patients at low immunological risk remains controversial, given increased risk of cytomegalovirus (CMV) infection*Methods: To investigate…2019 American Transplant Congress
Comparison of Long-Term Outcomes between Alemtuzumab and Rabbit Anti-Thymocyte Globulin for Acute Kidney Allograft Rejection
Erasmus MC, Rotterdam, Netherlands
*Purpose: T cell-depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the treatment of choice for glucocorticoid-resistant, recurrent and/or severe acute kidney allograft rejection (AR).…2019 American Transplant Congress
Case Series: Anti-Thymocyte Globulin as a Treatment for Steroid-Refractory Severe Acute Hepatitis in Children
*Purpose: Pediatric severe acute hepatitis (SAH), when not attributed to acetaminophen toxicity, is commonly hypothesized to be caused by a non-typeable viral infection and/or immune…2019 American Transplant Congress
ABMR In Low-single Dose Thymoglobulin Induction Protocol In Renal Transplant Recepients From A Tertiary Care Centre In A Developing Country
*Purpose: Fool proof induction therapy in low sensitized patients is still elusive. There is a thin line between over immunosuppression and infection . Conventional rabbit…2019 American Transplant Congress
Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients
*Purpose: Post-transplant malignancy is diagnosed in approximately 18% of heart transplant (HTx) recipients and is a leading long-term cause of death among these patients. The…2018 American Transplant Congress
Comparison of Induction and Maintenance Immunosuppression Regimens in Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Registry
Aim: Induction and maintenance immunosuppression regimens in intestinal transplant widely vary among centers. The aim of this study was to investigate an association between immunosuppression…2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »